Celcuity
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 55
- Market Cap
- -
- Introduction
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Celcuity's Gedatolisib Shows Promising Results in Prostate and Breast Cancer Trials
Celcuity reported a 66% six-month radiographic progression-free survival rate for gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer patients.
Gedatolisib Shows Promising 77-Month Overall Survival in Advanced Breast Cancer Phase 1b Trial
Phase 1b trial demonstrates gedatolisib combination therapy achieved 77.3 months median overall survival in treatment-naïve HR+/HER2- advanced breast cancer patients.
Celcuity's Gedatolisib Projected to Reach $155M Annual Revenue by 2034 for Breast Cancer Treatment
Gedatolisib, a dual PI3K/mTOR inhibitor developed by Celcuity, shows promising market potential with projected annual revenue of $155 million by 2034 in the US market.